received placebo treatment led reductions brain amyloid believed play key role development alzheimer symptoms according interim data presented 12th international conference alzheimer parkinson diseases related neurological disorders nice france friday plaque reduction pronounced dose drug increased time marks time experimental drug demonstrated statistically significant reduction amyloid plaque slowing clinical impairment patients mild disease said alfred sandrock biogen chief medical officer bigger treatment effect hoped sandrock said biogen begin enrolling patients later year large phase iii trial seek approval drug biogen said increased chances success carefully screening patients exclude forms dementia misdiagnosed alzheimer testing early disease imaged patient coming study knew